Skip to main content

Table 2 Phase 11/III clinical trials of anti-VEGF tyrosine kinase inhibitors agents in advanced gastric cancer

From: Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials

Drug Number of patients Line ORR (%) PFS (months) [HR (95% CI), p value] OS (months/days) [HR (95% CI), p value]
Sunitinib 78 2 3.9 31.28   5.81  
Sorafenib 44 1 41 5.8   13.6  
Apatinib (850 mg) 270 1      
 Apatinib group 180 2.84 78 HR 0.44, 95% CI 0.33–0.61
p < 0.0001
195 days HR 0.71, 95% CI 0.54–0.94
p < 0.06
 Placebo group 90 0.00 53 140 days
Trebananib 171 1      
 Treb (10 mg)    27 4.2 HR 0.98
95% CI 0.67–1.43
p = 0.92
NR  
 Treb (3 mg)    43 4.9 NR  
 Ch + placebo    35 5.2 NR  
Regorafenib 147 1      
 Rego group 97   NR 11.1   25 weeks  
 Placebo group 50   NR 3.9 p = 0.0001 19.4 weeks p = 0.11
  1. ORR median overall response rate, TTP median time to progression, PFS median progression-free survival, OS median overall survival, HR hazard ratio, CI confidence interval, Ch chemotherapy, Treb Trebananib, NR not reported